Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

nhibitors; and the enabling capabilities of Cytokinetics biological focus. Such statements are based on management s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, that GSK or the NCI may decide to postpone or discontinue development efforts for GSK-923295 or ispinesib, respectively; that there may be difficulties or delays potential difficulties or delays in the development, testing, regulatory approval, production and marketing of Cytokinetics drug candidates that could slow or prevent clinical development, product approval or market acceptance, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results, patient enrollment for clinical trials may be difficult or delayed, Cytokinetics drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy, and Cytokinetics may not be able to obtain and maintain patent or trade secret protection for its intellectual property; that Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing if necessary; and that standards of care may change or others may introduce products or alternative therapies for the treatment of indications which Cytokinetics drug candidates and potential drug candidates currently or potentially target. For further information regarding these and other risks related to Cytokinetics business, investors should consult Cytokinetics filings with the Securities and Exchange Commission.


'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
(Date:8/28/2015)... , August 28, 2015 The report "Eubiotics ... (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by Region ( ... Asia-Pacific , and Rest of the World) - ... global market for Eubiotics was valued at USD 4.62 Billion ... by 2020, at a CAGR of 7.4% from 2015 to ...
(Date:8/27/2015)... , Aug. 27, 2015  The Academy of ... and Drug Administration,s (FDA,s) draft guidance and proposed ... and biosimilars, to bear a nonproprietary name with ... been seeking a decision from the FDA on ... health care stakeholders urging the agency to use ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2
... Nashville, Tenn., Oct. 29 Cumberland ... Pty Ltd., an Australian-based specialty pharmaceutical company, today announced ... commercialization of Caldolor® (ibuprofen) Injection in Australia and New ... to treat pain and fever in the hospital setting. ...
... at Thomas Jefferson University in Philadelphia, PA, supported in part ... Journal of Nuclear Medicine reporting preclinical results of a novel ... [1] . "All tumors detected with the new ... on the plasma membrane of the tumor cells." These results ...
Cached Medicine Technology:Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 2Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 3Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 4Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 5New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors 2New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors 3
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and President of ... increase acceptance of the chiropractic field in the military. All too often VA hospitals ... Chiropractic was made available to the VA program over a decade ago, the reality ...
(Date:8/29/2015)... ... , ... ProDrop Particles includes over 40 particle backdrops designed for use in ... that users can shrink and stretch in the Final Cut Pro X timeline. Choose ... brightness, scale, speed, range, and flare attributes with intuitive controls found in the top-right ...
(Date:8/29/2015)... ... ... The popular television program VOICES IN AMERICA, hosted by legendary star of the stage ... short segment to the subject of diabetes. Diabetes is a debilitating health condition that ... recent advancements in medical science may prove to be a significant breakthrough that sufferers ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a growing number of ... transitioned management companies to partner with Wound Care Advantage (WCA) to utilize the ... , Transitioning wound care management providers can be a complex undertaking. WCA ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce ... the position they are applying for, they are unable to pass the initial drug ... altering drug testing policies in order to be able to hire long-term, skilled talent. ...
Breaking Medicine News(10 mins):Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... Help Plan Members Better Manage Healthcare Needs and Spending , ... Life Insurance Company of America (Guardian), one of the largest ... voluntary benefits for small and mid-sized companies, today introduced enhanced ... their employees will now have access to a broad range ...
... Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical ... novel drugs in the therapeutic areas of infection, oncology ... the first quarter ended March 31, 2009. The ... months ended March 31, 2009 was $2.3 million or ...
... ,Eliminates Complications Including Right Heart Failure , ... ... to INTERMACS data recently published in SynCardia’s 2008 Annual ... a bridge-to-transplant rate of 72% at 6 months. This is ...
... Call to Action demonstrates commitment to combating a leading ... and WaterAid America released two new reports today that ... are not responding to clear evidence on child mortality ... Diarrheal disease, a leading killer of children under age ...
... www.hairfairies.com ) opens new salon to help San Diego,s frantic families ... 12 Hair Fairies, the head lice helpers, ( www.hairfairies.com ) ... lice removal salon in San Diego on May 12, 2009. ... a nationwide, full service salon dedicated to removing head lice. ...
... 12 Miami and NY-based Jeffrey Epstein, M.D., FACS, ... has recently established The Foundation for Hair Restoration and ... surgical hair restoration and plastic surgeons. Recognized for ... will help to position The Foundation for Hair Restoration ...
Cached Medicine News:Health News:Guardian Enhances Medical Plans With New Wellness Benefits 2Health News:Guardian Enhances Medical Plans With New Wellness Benefits 3Health News:Guardian Enhances Medical Plans With New Wellness Benefits 4Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 2Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 3Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 4Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 5Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 6Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 7Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 8Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 9Health News:INTERMACS: Total Artificial Heart Bridge-to-Transplant Rate 2x Higher ,at 6 Months Than BiVADS and LVADs 2Health News:Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6 Million Children Die Each Year From These Preventable and Treatable Diseases 2Health News:Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6 Million Children Die Each Year From These Preventable and Treatable Diseases 3Health News:Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6 Million Children Die Each Year From These Preventable and Treatable Diseases 4Health News:Lice Removal Salon Offers San Diego an Upscale Solution to an Undesirable Problem 2Health News:Foundation for Hair Restoration Brings Breakthrough Surgical Technology to the U.S. and Announces Nationwide Expansion of Its Network of Top Doctors 2
... reagents for the detection of two ... G1691A mutation on the Factor V ... on the Prothrombin gene. Laboratories may ... tests.,, *Analyte Specific Reagents. ...
... the latest and most advanced fecal occult ... line. An immunochemical FOBT (iFOBT) with high ... proven to detect bleeding associated with more ... Because of its superior specificity for lower ...
... When treating a female patient, it's ... of an undetected pregnancy with a ... results at the lowest hCG levels. ... test kit provides semi-quantitative determination of ...
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: